ReviewCells2021
Human Neural Stem Cells for Cell-Based Medicinal Products.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.Applied biochemistry and biotechnology · 2026Review
- Neural Stem/Progenitor Cells Regulate Neuroinflammation: Mechanisms and Therapeutic Applications in Neurological Diseases.International journal of molecular sciences · 2026Review
- Review
- Molecular and functional characterization of GMP-manufactured neural stem cells and their extracellular vesicles for innovative therapeutic applications.Stem cell research & therapy · 2026Article
- Molecular Mechanisms and Clinical Applications of Neural Regeneration Through Dental Pulp Stem Cells.Stem cells international · 2026Review
- Application of stem cells in the precise diagnosis and treatment of liver diseases.World journal of gastroenterology · 2025Review
- Drivers and implications of lineage-specific cancer-related mutations in human pluripotent and adult stem cells.Stem cell reports · 2025Article
- Combined mesenchymal and neural stem cell therapy enhances neurological recovery in cerebral infarction.World journal of stem cells · 2025Article
- A review on current theories and potential therapies for prion diseases.Molecular biology reports · 2025Review
- Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives.Molecular neurobiology · 2025Review
- Preclinical efficacy and safety assessments of Adult human neural stem cells (AhNSCs) for spinal cord injury.Toxicology reports · 2025Article
- Body Fluid-Derived Stem Cells: Powering Innovative, Less-Invasive Cell Therapies.International journal of molecular sciences · 2025Review
- Clinical applications of stem cell-derived exosomes.Signal transduction and targeted therapy · 2024Review
- Review
- Research progress and challenges of stem cell therapy for ischemic stroke.Frontiers in cell and developmental biology · 2024Review
- Neural stem cells for Parkinson's disease management: Challenges, nanobased support, and prospects.World journal of stem cells · 2023Review
- Role of brahma-related gene 1/brahma-associated factor subunits in neural stem/progenitor cells and related neural developmental disorders.World journal of stem cells · 2023Review
- Article
- Brain Organoids to Evaluate Cellular Therapies.Animals : an open access journal from MDPI · 2022Article
- Stable expression of a truncated TLX variant drives differentiation of induced pluripotent stem cells into self-renewing neural stem cells for production of extracellular vesicles.Stem cell research & therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Neural stem cells represent an attractive tool for the development of regenerative therapies and are being tested in clinical trials for several neurological disorders. Human neural stem cells can be isolated from the central nervous system or can be derived in vitro from pluripotent stem cells. Embryonic sources are ethically controversial and other sources are less well characterized and/or inefficient. Recently, isolation of NSC from the cerebrospinal fluid of patients with spina bifida and with intracerebroventricular hemorrhage has been reported. Direct reprogramming may become another alternative if genetic and phenotypic stability of the reprogrammed cells is ensured. Here, we discuss the advantages and disadvantages of available sources of neural stem cells for the production of cell-based therapies for clinical applications. We review available safety and efficacy clinical data and discuss scalability and quality control considerations for manufacturing clinical grade cell products for successful clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.